The shares of Nektar Therapeutics (NASDAQ:NKTR) has been pegged with a rating of Neutral by H.C. Wainwright in its latest research note that was published on June 11th, 2018. The research company has also assigned a $54 price target. H.C. Wainwright wasn’t the only research firm that published a report of Nektar Therapeutics, with other equities research analysts also giving their opinion on the stock. H.C. Wainwright advised investors in its research note published on June 4th, 2018, to Buy the NKTR stock while also putting a $97 price target. The stock had earned Buy rating from Seaport Global Securities when it published its report on April 20th, 2018. That day the Seaport Global Securities set price target on the stock to $120. The stock was given Overweight rating by Piper Jaffray in its report released on April 13th, 2018, the day when the price target on the stock was placed at $125. Mizuho was of a view that NKTR is Buy in its latest report on April 6th, 2018 while giving it a price target of $103. H.C. Wainwright thinks that NKTR is worth Buy rating. This was contained in the firm’s report on April 2nd, 2018 in which the stock’s price target was also moved to $125.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 2 believe it has the potential for further growth, thus rating it as Hold while 4 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $81.00. The price of the stock the last time has raised by 13.43% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 42.98.
The shares of the company dipped by -6.24% during the trading session on Tuesday, reaching a low of $37.79 while ending the day at $38.00. During the trading session, a total of 2.74 million shares were traded which represents a -11.03% decline from the average session volume which is 2.47M shares. NKTR had ended its last session trading at 40.53. Nektar Therapeutics currently has a market cap of $6.56B, while its P/E ratio stands at 9.59, while its P/E earnings growth sits at 5.25, with a beta of 2.81. Nektar Therapeutics debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 13.80. NKTR 52-week low price stands at $33.50 while its 52-week high price is $111.36.
The Nektar Therapeutics generated $27.76 million in revenue during the last quarter, which is slightly higher than the $26.08 million predicted by analysts. Nektar Therapeutics has the potential to record 3.96 EPS for the current fiscal year, according to equities analysts.
Investment analysts at The Benchmark Company published a research note on September 25th, 2018 where it informed investors and clients that Canopy Growth Corporation (NYSE:CGC) is now rated as Buy. H.C. Wainwright also rated CGC as Reiterated on June 4th, 2018, with its price target of $97 suggesting that CGC could down by -INF% from its current share price. It started the day trading at $33.16 and traded between $31.22 and $31.45 throughout the trading session.
A look at its technical shows that CGC’s 50-day SMA is 41.46 while its 200-day SMA stands at 32.72. The company’s average trading volume currently stands at 13.47M shares, which means that the short-interest ratio is just 1.56 days. Over the past seven days, the company moved, with its shift of -0.79%. Looking further, the stock has dropped -39.52% over the past 90 days while it gained 0.06% over the last six months.